**MARKET & SUPPLY UPDATE**

**COVID-19 Vaccine**

**CONTEXT**

- In May, WHO declared the end of the COVID-19 Pandemic as a Public Health Emergency of International Concern (PHEIC). COVID-19 Pandemic is far from over and remains an ongoing public health issue.

- Since 2021, UNICEF has procured COVID-19 vaccines of assured quality for COVAX, AVAT and others, and facilitated delivery of donated vaccine doses and will continue doing so under the C19 programme.

- As of September 2023, UNICEF together with PAHO has delivered more than 1.96 billion doses of Covid-19 vaccines to 146 participants of the COVAX Facility. Furthermore, UNICEF has delivered more than 146.8 million doses to 45 countries on behalf of AVAT. In total, 2.1 billion doses across 4 platforms, supplied from 8 manufacturers, have been delivered since 2021 to COVAX, AVAT and on behalf of other clients through UNICEF’s procurement services function.

**SUPPLY & DEMAND**

- COVAX will sunset on 31 December 2023. The AVAT agreement will also conclude in 2023.

- The Gavi Board in June approved the C19 programme to support Covid-19 vaccine to high-risk populations in the AMC 91 countries for 2024 and 2025.

- The Gavi approved and funded C19 programme will have three sources of supply: (i) Tendered LTAs, (ii) APA Spillover, and (iii) Donations.

- Deliveries under the new C19 programme, aligned with the SAGE Prioritization Roadmap and focusing on securing booster doses for high priority groups (older adults, adults with comorbidities, immunocompromised individuals (incl. children & adolescents), pregnant persons and frontline healthcare workers) in GAVI54 and AMC37 countries will begin in January 2024.

- Expected demand for Covid-19 vaccines to be secured through the C19 Programme in 2024 ranges between a low and high range of 45-90 millions doses (to be confirmed in second half of 2023).

**ISSUES & CHALLENGES**

- As Covid-19 continues to evolve, so does the development of new variants and with it, the vaccine composition.

- Demand predictability remains low, while countries work on determining how/whether they will integrate Covid-19 into their routine immunization planning.

- September SAGE recommendations on use of the vaccine (including variant vaccines) are expected to impact country product preference in Low/Middle Income Countries, as will the product preference of High-Income Countries.

**LOOKING AHEAD**

- UNICEF is in the process of finalizing the C19 tender that closed on 16 June, and is expected to award and enter LTAs in September

- UNICEF continues to be guided by the principle of Vaccine Security – the uninterrupted, sustainable supply of affordable vaccines of assured quality – ensuring available funding for vaccines, accurate forecasting and appropriate contracting.

- Price Transparency, Good Faith Agreements and a return to the assumption of standard product liability by manufacturers are key priorities.

---

**VACCINE INDUSTRY CONSULTATION 2023**

**FURTHER QUESTIONS OR ADDITIONAL INFORMATION? PLEASE CONTACT:**

Siri Bjornstad
Contracts Manager
sbjornstad@unicef.org

https://www.unicef.org/supply/